NCT03190369 - Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee | Biotech Hunter

Enrollment

440

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

January 28, 2019

Study Completion Date

January 28, 2019

Conditions

Osteoarthritis

Interventions

DEVICE

Hylan G-F 20 (GZ402662/SAR402662)

"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"

DRUG

Placebo

"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"

Trial Locations (21)

100044

Investigational Site Number 1560001, Beijing

100050

Investigational Site Number 1560005, Beijing

100191

Investigational Site Number 1560020, Beijing

100730

Investigational Site Number 1560009, Beijing

130021

Investigational Site Number 1560012, Changchun

200011

Investigational Site Number 1560002, Shanghai

200032

Investigational Site Number 1560003, Shanghai

200072

Investigational Site Number 1560022, Shanghai

210009

Investigational Site Number 1560019, Nanjing

210029

Investigational Site Number 1560021, Nanjing

214023

Investigational Site Number 1560008, Wuxi

266003

Investigational Site Number 1560007, Qingdao

300052

Investigational Site Number 1560010, Tianjin

300192

Investigational Site Number 1560015, Tianjin

410008

Investigational Site Number 1560013, Changsha

430033

Investigational Site Number 1560006, Wuhan

510080

Investigational Site Number 1560016, Guangzhou

610041

Investigational Site Number 1560023, Chengdu

650032

Investigational Site Number 1560017, Kunming

010017

Investigational Site Number 1560011, Hohhot

030001

Investigational Site Number 1560018, Taiyuan

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY